FLGT
Fulgent Genetics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+4/100
Last price
20.59
▼ 1.86 (8.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
22.45
Prev close
22.45
Day high
22.78
Day low
20.47
Volume
368.61K
Market cap
$566.26M
P/E (TTM)
—
52W range
13.46 – 31.04
Day trading desk
Gap from prior close
+0.00%
Prior close 22.45
VWAP
21.04
-2.14% from price
Relative volume
1.09×
Normal
Session range
11.28%
20.47 – 22.78
Position in range
5%
Near session low
ATR (14D)
0.80
3.91% of price
Prior day high
22.47
PDH
Prior day low
21.28
PDL
Bid / ask spread
—
Quote not published
Session volume
324.42K
Avg 296.61K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.79%
-8.7%
1M
+4.31%
+3.2%
3M
-0.15%
-4.7%
6M
+29.35%
+11.2%
YTD
-21.66%
-35.9%
1Y
-9.66%
-26.1%
3Y
-23.04%
-105.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FLGT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.88K
Net buying
Buy transactions
3
27.79K shares
Sell transactions
8
11.91K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
10.39M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | GAO HANLIN Officer |
SELL | 1.67K | $32.88K | Direct |
| Sep 2, 26 | XIE JIAN President |
SELL | 2.13K | $41.81K | Direct |
| Aug 27, 26 | GAO HANLIN Officer |
SELL | 939 | $18.69K | Direct |
| Aug 27, 26 | XIE JIAN President |
SELL | 1.19K | $23.75K | Direct |
| Jun 2, 26 | GAO HANLIN Officer |
SELL | 1.69K | $30.19K | Direct |
| Jun 2, 26 | XIE JIAN President |
SELL | 2.15K | $38.38K | Direct |
| May 27, 26 | GAO HANLIN Officer |
SELL | 945 | $16.63K | Direct |
| May 27, 26 | XIE JIAN President |
SELL | 1.20K | $21.14K | Direct |
| May 14, 26 | GROVES REGINA E Director |
STOCK | 11.12K | $0 | Direct |
| May 14, 26 | NOHAILE MICHAEL Director |
STOCK | 5.56K | $0 | Direct |
| May 14, 26 | DONG LINDA Director |
STOCK | 11.12K | $0 | Direct |
| Feb 24, 26 | GAO HANLIN Officer |
STOCK | 67.12K | $0 | Direct |
| Feb 24, 26 | HSIEH MING Chief Executive Officer |
STOCK | 187.44K | $0 | Direct |
| Feb 24, 26 | XIE JIAN President |
STOCK | 80.46K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DONG LINDA |
Director | 38.76K | Stock Award(Grant) |
GAO HANLIN |
Officer | 986.12K | Sale |
GROVES REGINA E |
Director | 28.10K | Stock Award(Grant) |
HSIEH MING |
Chief Executive Officer | 9.04M | Stock Award(Grant) |
KIM PAUL |
Chief Financial Officer | 379.19K | Stock Award(Grant) |
MARSH LINDA |
Director | 27.64K | Stock Award(Grant) |
NOHAILE MICHAEL |
Director | 24.58K | Stock Award(Grant) |
XIE JIAN |
President | 580.74K | Sale |
Fundamentals
Market cap$566.26M
Enterprise value$313.20M
Revenue (TTM)$323.93M
Gross profit$115.26M
EBITDA$-89.46M
Net income$-84.38M
EPS (TTM)$-2.94
Free cash flow$-90.90M
Total cash$257.03M
Total debt$9.60M
Book value / share$36.40
Shares outstanding27.52M
Float16.69M
Short % of float13.53%
Dividend yield0.00%
Beta (5Y)0.93
Valuation & profitability ratios
Trailing P/E—
Forward P/E-14.91
PEG ratio—
Price / sales—
Price / book0.57
EV / revenue0.97
EV / EBITDA-3.50
Gross margin35.58%
Operating margin-39.35%
Profit margin-26.05%
Return on equity-8.11%
Return on assets-6.30%
Debt / equity0.96
Current ratio6.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $322.67M | $283.47M | $289.21M | $618.97M | +13.8% |
| Operating revenue | $322.67M | $283.47M | $289.21M | $618.97M | +13.8% |
| Cost of revenue | $191.80M | $176.25M | $184.76M | $252.07M | +8.8% |
| Gross profit | $130.88M | $107.22M | $104.46M | $366.90M | +22.1% |
| Research & development | $53.91M | $48.82M | $41.44M | $28.91M | +10.4% |
| Selling, general & admin | $160.03M | $124.35M | $130.47M | $149.99M | +28.7% |
| Total operating expense | $221.97M | $181.13M | $179.75M | $185.40M | +22.5% |
| Operating income | -$91.10M | -$73.92M | -$75.30M | $181.50M | -23.2% |
| Net interest income | $30.84M | $31.47M | $21.12M | $4.61M | -2.0% |
| Pre-tax income | -$70.03M | -$51.96M | -$174.09M | $184.03M | -34.8% |
| Tax provision | -$8.39M | -$8.14M | $1.15M | $42.10M | -3.2% |
| Net income | -$60.51M | -$42.71M | -$167.82M | $143.40M | -41.7% |
| Net income to common | -$60.51M | -$42.71M | -$167.82M | $143.40M | -41.7% |
| Basic EPS | -1.97 | -1.41 | -5.63 | 4.76 | -39.7% |
| Diluted EPS | -1.97 | -1.41 | -5.63 | 4.63 | -39.7% |
| EBIT | -$69.95M | -$73.92M | -$173.60M | $185.04M | +5.4% |
| EBITDA | -$45.83M | -$48.99M | -$147.45M | $217.70M | +6.5% |
| Basic shares | 30.78M | 30.23M | 29.78M | 30.10M | +1.8% |
| Diluted shares | 30.78M | 30.23M | 29.78M | 30.96M | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $50.19M | $55.14M | $97.47M | $79.51M | -9.0% |
| Cash & short-term investments | $336.08M | $258.11M | $424.15M | $526.24M | +30.2% |
| Accounts receivable | $84.76M | $69.02M | $51.13M | $52.75M | +22.8% |
| Inventory | $10.60M | $8.38M | $5.83M | $4.28M | +26.5% |
| Total current assets | $550.49M | $353.57M | $507.85M | $627.87M | +55.7% |
| Property, plant & equipment | $112.55M | $105.55M | $83.46M | $81.35M | +6.6% |
| Goodwill & intangibles | $158.36M | $157.03M | $165.11M | $293.67M | +0.8% |
| Total assets | $1.21B | $1.22B | $1.24B | $1.39B | -0.5% |
| Total current liabilities | $84.97M | $72.90M | $73.02M | $88.11M | +16.6% |
| Current debt | $476.00K | $412.00K | $1.18M | $20.64M | +15.5% |
| Long-term debt | $1.96M | $2.49M | $2.96M | $3.37M | -21.5% |
| Total debt | $7.68M | $8.47M | $15.25M | $38.94M | -9.3% |
| Total liabilities | $106.81M | $90.81M | $102.04M | $116.18M | +17.6% |
| Retained earnings | $529.95M | $590.47M | $633.17M | $801.00M | -10.2% |
| Shareholder equity | $1.11B | $1.13B | $1.14B | $1.27B | -1.9% |
| Working capital | $465.52M | $280.67M | $434.83M | $539.77M | +65.9% |
| Net tangible assets | $953.63M | $976.20M | $970.99M | $973.01M | -2.3% |
| Shares issued | 34.50M | 33.61M | 32.42M | 29.44M | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$61.63M | -$43.82M | -$175.24M | $141.92M | -40.6% |
| Depreciation & amortisation | $24.12M | $24.93M | $26.14M | $32.66M | -3.2% |
| Stock-based compensation | $39.58M | $44.48M | $42.92M | $32.64M | -11.0% |
| Change in working capital | -$117.63M | -$7.24M | $2.84M | $2.00M | -1,525.0% |
| Operating cash flow | -$101.64M | $21.06M | $27.00M | $253.52M | -582.6% |
| Capital expenditure | -$22.57M | -$40.31M | -$22.21M | -$18.77M | +44.0% |
| Investing cash flow | $111.37M | -$58.35M | $38.90M | -$261.31M | +290.9% |
| Share buybacks | -$13.92M | -$3.12M | -$27.79M | -$76.11M | -345.6% |
| Financing cash flow | -$14.79M | -$4.85M | -$47.78M | -$77.14M | -205.1% |
| Free cash flow | -$124.21M | -$19.25M | $4.80M | $234.75M | -545.1% |
| End cash position | $50.33M | $55.28M | $97.47M | $79.51M | -9.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $85.39M | $71.14M | $83.34M | $84.07M | $81.80M | +20.0% |
| Operating revenue | $85.39M | $71.14M | $83.34M | $84.07M | $81.80M | +20.0% |
| Cost of revenue | $59.71M | $49.65M | $50.75M | $48.56M | $47.37M | +20.3% |
| Gross profit | $25.68M | $21.49M | $32.58M | $35.51M | $34.44M | +19.5% |
| Research & development | $14.55M | $14.18M | $14.17M | $13.86M | $13.48M | +2.7% |
| Selling, general & admin | $42.42M | $39.91M | $52.62M | $34.98M | $38.68M | +6.3% |
| Total operating expense | $59.58M | $56.11M | $68.82M | $50.86M | $54.15M | +6.2% |
| Operating income | -$33.90M | -$34.62M | -$36.24M | -$15.35M | -$19.71M | +2.1% |
| Net interest income | $6.34M | $8.63M | $6.92M | $7.85M | $8.07M | -26.5% |
| Pre-tax income | -$29.69M | -$25.98M | -$29.27M | -$7.51M | -$21.52M | -14.3% |
| Tax provision | $29.00K | -$704.00K | -$5.62M | -$683.00K | -$2.26M | +104.1% |
| Net income | -$29.53M | -$24.83M | -$23.42M | -$6.61M | -$18.96M | -18.9% |
| Net income to common | -$29.53M | -$24.83M | -$23.42M | -$6.61M | -$18.96M | -18.9% |
| Basic EPS | -1.05 | -0.80 | -0.76 | -0.21 | -0.62 | -31.3% |
| Diluted EPS | -1.05 | -0.80 | -0.76 | -0.21 | -0.62 | -31.3% |
| EBIT | -$29.63M | -$25.96M | -$29.26M | -$7.48M | -$21.50M | -14.1% |
| EBITDA | -$21.95M | -$19.96M | -$23.15M | -$1.44M | -$15.45M | -10.0% |
| Basic shares | 28.00M | 30.88M | 30.98M | 30.75M | 30.54M | -9.3% |
| Diluted shares | 28.00M | 30.88M | 30.98M | 30.75M | 30.54M | -9.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.30M | $23.40M | $50.19M | $117.64M | $87.88M | +12.4% |
| Cash & short-term investments | $257.03M | $276.30M | $336.08M | $375.80M | $292.93M | -7.0% |
| Accounts receivable | $64.94M | $69.28M | $84.76M | $71.19M | $77.19M | -6.3% |
| Inventory | $11.67M | $12.06M | $10.60M | $10.06M | $8.98M | -3.2% |
| Total current assets | $454.77M | $479.04M | $550.49M | $507.37M | $428.73M | -5.1% |
| Property, plant & equipment | $113.07M | $116.34M | $112.55M | $111.86M | $110.22M | -2.8% |
| Goodwill & intangibles | $203.12M | $207.72M | $158.36M | $160.34M | $153.12M | -2.2% |
| Total assets | $1.09B | $1.16B | $1.21B | $1.21B | $1.20B | -5.8% |
| Total current liabilities | $71.76M | $90.13M | $84.97M | $72.43M | $71.33M | -20.4% |
| Current debt | $482.00K | $482.00K | $476.00K | $476.00K | $476.00K | 0.0% |
| Long-term debt | $1.48M | $1.48M | $1.96M | $1.96M | $1.96M | 0.0% |
| Total debt | $9.42M | $9.90M | $7.68M | $7.54M | $7.39M | -4.8% |
| Total liabilities | $93.24M | $112.22M | $106.81M | $93.81M | $88.20M | -16.9% |
| Retained earnings | $475.60M | $505.13M | $529.95M | $553.37M | $559.98M | -5.8% |
| Shareholder equity | $1.00B | $1.05B | $1.11B | $1.13B | $1.12B | -4.6% |
| Working capital | $383.01M | $388.91M | $465.52M | $434.95M | $357.39M | -1.5% |
| Net tangible assets | $798.50M | $842.09M | $953.63M | $965.55M | $963.47M | -5.2% |
| Shares issued | 27.52M | 34.87M | 34.50M | 34.27M | 34.03M | -21.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$29.72M | -$25.27M | -$23.65M | -$6.83M | -$19.26M | -17.6% |
| Depreciation & amortisation | $7.68M | $6.00M | $6.11M | $6.04M | $6.05M | +27.9% |
| Stock-based compensation | $8.62M | $9.89M | $9.28M | $9.72M | $10.04M | -12.8% |
| Change in working capital | -$15.63M | $16.76M | -$71.71M | $2.38M | -$38.52M | -193.3% |
| Operating cash flow | -$23.76M | $7.10M | -$78.14M | $11.11M | -$30.17M | -434.8% |
| Capital expenditure | -$3.86M | -$5.20M | -$4.98M | -$6.05M | -$6.83M | +25.8% |
| Investing cash flow | $50.80M | $10.94M | $11.15M | $19.08M | $53.40M | +364.4% |
| Share buybacks | -$24.14M | -$44.28M | -$447.00K | -$357.00K | -$2.55M | +45.5% |
| Financing cash flow | -$24.23M | -$44.83M | -$534.00K | -$445.00K | -$2.64M | +46.0% |
| Free cash flow | -$27.62M | $1.90M | -$83.12M | $5.06M | -$37.00M | -1,557.3% |
| End cash position | $26.44M | $23.53M | $50.33M | $117.78M | $88.02M | +12.3% |
Options analytics
Put / call volume
1.33
Put-heavy session
Put / call open interest
0.23
Positioning, not flow
Max pain
17.50
-15.0% from spot
ATM implied vol
77.2%
Nearest strike to spot
Skew (10% OTM)
-23.0%
Calls bid over puts
Call volume
127
Contracts, this expiry
Put volume
169
Contracts, this expiry
Heaviest call OI
20.00
464 contracts
Heaviest put OI
20.00
105 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.44 | -0.58 | -32.2% |
| Mar 2026 | -0.35 | -0.36 | -3.4% |
| Dec 2025 | 0.03 | 0.16 | +436.4% |
| Sep 2025 | -0.22 | 0.14 | +162.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.65 | 1 | $86.30M | +2.7% |
| Next quarter | -0.69 | 1 | $88.90M | +6.7% |
| Current year | -2.27 | 1 | $331.70M | +2.8% |
| Next year | -1.38 | 1 | $382.70M | +15.4% |
Analyst targets & ownership
Mean target$19.00
High target$19.00
Low target$19.00
Implied upside-7.72%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell0 / 0
Held by insiders37.75%
Held by institutions58.40%
Institutions holding217
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
21.73
-5.24% from price
SMA 20
21.40
-3.83% from price
SMA 50
20.09
+2.44% from price
SMA 100
19.52
+5.46% from price
SMA 200
19.95
+3.16% from price
EMA 12
21.53
-4.36% from price
EMA 26
21.11
-2.45% from price
EMA 50
20.51
+0.40% from price
RSI (14)
45.9
Neutral
MACD (12,26,9)
0.42
Hist -0.12
ATR (14)
0.80
3.91% of price
Realised vol 30D
38.0%
Annualised
Bollinger upper
22.83
20, 2σ
Bollinger lower
19.97
20, 2σ
50 / 200 cross
Golden
20.09 vs 19.95
Trend bias
Above 200
+3.16%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.76
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
38.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.3%
Peak to trough
Max drawdown 5Y
-86.9%
Peak to trough
ATR 14
0.80
3.91% of price
Beta (reported)
0.93
5Y monthly, from filing
Short interest
Shares short
2.32M
Prior 2.56M
Change vs prior
-9.3%
Shorts covering
% of float
13.53%
Elevated
% of shares out
8.42%
Against total outstanding
Days to cover
8.0
Crowded exit
Float
16.69M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| May 5, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Nov 11, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Aug 5, 25 | UBS | UPGRADE | Neutral | Buy |
| Aug 4, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| May 6, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| May 5, 25 | Raymond James | MAINTAINED | Outperform | Outperform |
| Mar 4, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Nov 11, 24 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Mar 6, 24 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Dec 7, 23 | UBS | INITIATED | — | Neutral |
| Oct 16, 23 | Piper Sandler | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-02
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-14
Periodic Financial Reports
10-Q · 2026-05-01
Proxy Statements
DEF 14A · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-03-17
Corporate Changes & Voting Matters
8-K · 2026-02-27
Headlines
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
Zacks · 14d ago
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
Motley Fool · 60d ago
Fulgent Genetics (FLGT) Stock Gets Fair Value Boost After Analysts Raised Targets
Simply Wall St. · 62d ago
Fulgent Genetics, Inc. Q2 2026 Earnings Call Summary
Moby · 68d ago
Fulgent Genetics Inc (FLGT) (Q2 2026) Earnings Call Highlights: Strategic Progress Amid Revenue ...
GuruFocus.com · 68d ago
Fulgent Genetics Q2 Earnings Call Highlights
MarketBeat · 68d ago
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 68d ago
Fulgent Reports Second Quarter 2026 Financial Results
Business Wire · 68d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.